Background: Disturbances of glucose metabolism are common in β-thalassemia major (β-TM).
The oral glucose tolerance test (OGTT) and hemoglobin A1c (HbA1c) are commonly used screening tools for diabetes and have been shown to be valid in individuals with obesity and family history of diabetes. However, the utility of HbA1c measurement is limited in patients with thalassemia and has been considered unreliable. 11, 12 This is because of the questionable accuracy of HbA1c in patients with homozygous hemoglobinopathies, because both hemoglobinopathies and transfusions are known to interfere with HbA1c analysis. 13 The use of HbA1c as a diagnostic marker for diabetes in hemolytic anemia has to be done with caution as it may be falsely increased or decreased depending on the proximity to transfusion, shortened erythrocyte lifespan, and the assay used. 14, 15 Fructosamine could be considered an alternative parameter to assess glycemic control in thalassemia patients 16 but recently, no relation was found between fructosamine levels and impaired glucose tolerance (IGT) in β-thalassemia. 15 Therefore, OGTT has been proposed as the recommended screening method for glucose abnormalities in thalassemia.
However, the OGTT procedure requires patients to fast, is cumbersome and time consuming. 17 The continuous glucose monitoring system (CGMS) is a new method, which enables more diagnostic accuracy and a better achievement of an optimal glycemic control with the privilege of having glucose readings in 24 hours. 12, 18 CGMS technology is expanding its benefits for diagnostic use and behavior modification in prediabetes especially in high risk adolescents like those with obesity with or without family history of diabetes, metabolic syndrome, cystic fibrosis, and thalassemia. 18, 19 CGMS reveals early abnormalities of glucose tolerance that remain undiagnosed by OGTT screening and are associated with worse lung function or a higher prevalence of Pseudomonas aeruginosa colonization in patients with cystic fibrosis. [20] [21] [22] CGMS is superior to OGTT and HbA1C in detecting early glycemic abnormalities in obese patients 23 and indicated the presence of significant dysglycemia in obese first-degree relatives of type 2 diabetes mellitus patients. 24 CGMS disclosed early and frequent hyperglycemia in nondiabetic patients with acute coronary syndromes. 25 However, only some studies 12, 17, 26, 27 investigated the use of CGMS in a small number of patients with β-thalassemia major (β-TM) (mostly adolescents or adults).
Therefore, we assessed the pattern of glucose homeostasis and detected early impairment in glucose metabolism and the prediabetic state in children and adolescents with β-TM comparing OGTT and CGMS.
| MATERIALS AND METHODS
This cross-sectional study was conducted on 200 patients with β-TM (aged ≤18 years and with serum ferritin ≥1000 μg/L) as confirmed by medical history, examination, and investigations including complete blood count (CBC), reticulocytic count, and markers of chronic hemolysis as well as qualitative and quantitative hemoglobin analysis using high-performance liquid chromatography (HPLC). 28 
| Routine clinical assessment
All included patients were subjected to detailed medical history with special emphasis on age, sex, consanguinity and socioeconomic class, age of diagnosis of thalassemia and disease duration, transfusion history with calculation of transfusion index (volume of transfused packed red cells in ml per kg body weight per year; expressed as the mean value in the last 2 years) and history of splenectomy or viral hepatitis. Anthropometric measurements were recorded and body mass index (BMI) was calculated with calculation of SD score (SDS)
for age and sex. 29 Pubertal stage was determined according to Tanner's classification. 30 Complete cardiac, chest, abdominal, and neurological examination was done to assess the presence of any complications (endocrinology, renal, or hepatic).
| Laboratory analysis
Laboratory investigations included CBC using Sysmex XT-1800i
(Sysmex, Kobe, Japan), random blood glucose (RBG) using Cobas Integra 800 analyzer; Roche Diagnostics, Mannheim, Germany, measurement of serum ferritin using Immulite 1000 analyzer (Siemens Healthcare Diagnostics, Marburg, Germany). Serum ferritin level was measured at study with calculation of the mean value of the last year prior to the study to know the ferritin trend. Hemoglobin analysis was done by HPLC using D-10 (BioRad, Marnes La Coquette, France).
Because we recruited patients from those who were regularly attending the hematology clinic for receiving blood transfusion during regular visits, RBG was an easier convenient method for those patients and an early step to select a group targeting the main aim.
We used the cutoff 7.8 mmol/L (140 mg/dL) previously reported in literature. [31] [32] [33] However, in our study, we did not depend on RBG as a diagnostic testing but TM patients with elevated RBG ≥7.8 mmol/L were subjected to confirmatory diagnostic tests; assessment of respectively, to assure accuracy and avoid result by chance. Sensor was removed after the completion of the measuring period. All candidates were instructed to follow the hospital regular balanced diet schedule with optimal macronutrient distribution to prevent overload of carbohydrate and fat consumption and to sustain ideal body weight and optimal growth. The carbohydrate content of the meals was 45% of the total daily calories. Carbohydrate counting was used. Carbohydrate intake from vegetables, fruits, whole grains, legumes, and dairy products was encouraged. The protein content of the meals was 20%
to 30% of total energy intake and the fat intake was 30% of the total caloric intake mainly monounsaturated fatty acid (MUFA) and polyunsaturated fatty acid (PUFA). 35 The maximum, minimum, average, and SD blood glucose as well as mean deviation glucose (MAD) were recorded. The diagnosis of glycemic status whether normal, impaired fasting glucose (IFG), IGT, or diabetes was done according to the criteria of the American Diabetes Association. 36 In the absence of published criteria for diagnosing glycemic abnormalities by CGMS, the same criteria were applied for both the OGTT results and the CGMS data as reported by Soliman et al. Table 2 . Using OGTT, 6 out of 20 patients (30%) had IGT and 7 (35%) patients were in the diabetic range. CGMS
showed that 7/20 (35%) patients had IGT and 13 (65%) patients had DM. The percentage of diabetic patients diagnosed by CGMS was significantly higher than that with OGTT (P = 0.012) ( Table 3) .
As diagnosed by CGMS, two of the studied 20 patients showed abnormal levels of fasting blood glucose (FBG) within diabetic range with FBG 7.3 and 8.4 mmol/L, respectively. Three out of the 20 β-TM patients with RBG ≥7.8 mmol/L had insulin resistance using HOMA-IR; two of those three patients had DM while the third one had IGTT using CGMS. Eight of our 13 diabetic patients diagnosed by CGMS had low fasting C peptide levels. Ten of the 13 patients with DM according to the CGMS had abnormal HbA1c readings within diabetic range (6.5%-9.9%) while five of the seven patients with IGT had HbA1c readings in the prediabetic range (5.7%-6.1%). All patients with DM were non-compliant to chelation therapy.
| Relation between serum ferritin and glucose alterations in β-TM patients
As shown in Table 4 , β-TM patients with serum ferritin ≥2500 μg/L had lower BMI SDS. All β-TM patients with serum ferritin ≥2500 μg/L were non-compliant to chelation; 65.7% of them were on desferrioxamine therapy while only 31.4% of them were on deferiprone therapy.
Moreover, β-TM patients with serum ferritin ≥2500 μg/L had higher 
| DISCUSSION
Worldwide, DM and IGT are still prevalent complications in β-TM patients with hyper-transfusion therapy. DM is responsible for significant morbidity and mortality in those patients. 38 CGMS is an FDAapproved device that records blood sugar levels throughout the day and night. It has the advantage of measuring glucose concentrations under the usual (day-to-day) real-life conditions of the patient. CGMS can help to identify fluctuations and trends that would otherwise go unnoticed with standard OGTT, intermittent finger stick, and HbA1c measurements. 26 Although CGMS becomes a routine part of diabetes management, 39 still its use as a diagnostic tool in children and adolescents with β-TM is not fully determined.
In this study, we showed the presence of glycemic abnormalities in pediatric patients with β-TM that differ by the different methods used. Using RBG, 20 patients (10%) had RBG ≥7.8 mmol/L. We included β-TM patients with serum ferritin ≥1000 μg/L because this cutoff denotes iron-overload and predisposes to complications. It has been linked to endocrine dysfunction and glucose abnormalities in several studies. [40] [41] [42] We found that 70% of the 20 β-TM patients with RBG ≥7.8 mmol/L had serum ferritin ≥2500 mg/dL, with a median serum ferritin of 4750 (2304.5-6500) μg/L. All β-TM patients with serum ferritin ≥2500 μg/L were non-compliant to chelation therapy. Abbreviations: BMI, body mass index; β-TM, β-thalassemia major; Hb; hemoglobin; HbF, fetal hemoglobin; HCV, hepatitis C virus; IQR, interquartile range; RBG, random blood glucose; #: chelating agent alone or combined; SDS, SD score; WBCs: white blood cells. Data were expressed as mean and SD where Student t test were used for comparisons or as median (IQR) using Mann-Whitney U tests for comparison unless specified as number (percentage) using χ 2 test for comparison.
Metwalley and El-Saied 44 evaluated glucose homeostasis in Egyptian children and adolescents with β-TM. The prevalence of diabetes was 5% (3 of 60) and IGT was 8% (5 of 60). FBG, 2-hour post-load plasma glucose, serum ferritin, ALT, fasting insulin level, and HOMA-IR were significantly elevated in patients compared with healthy controls. The difference was more evident in patients with abnormal
OGTT and those who did not receive chelation or were on irregular chelation therapy. Therefore, they suggested regular iron chelation for thalassemia patients to improve glucose hemostasis and recommended that OGTT and HOMA-IR should be an integral part of the long-term follow-up of children and adolescents with β-TM.
44
However in our study, OGTT diagnosed glycemic abnormalities in 65% of β-TM patients with RBG ≥7.8 mmol/L, whereas CGMS diagnosed 100% of patients. DM was diagnosed in 65% of our patients using CGMS whereas only 35% were diagnosed by OGTT. Thus, CGMS seemed to be more sensitive and superior to the conventional OGTT or HbA1c. Abbreviations: AUC, area under the curve; β-TM, β-thalassemia major; FBG, fasting blood glucose; HOMA-IR, homeostatic model assessment insulin resistance; HBA1c, hemoglobin A1c; IQR, interquartile range; MAD, mean average deviation; PPBG: postprandial blood glucose; RBG: random blood glucose; . Albaker et al 12 investigated six non-diabetic, transfusiondependent β-thalassemia patients aged 9 to 13 years old. Patients were connected to CGMS for 1 day; three patients were found to have abnormal glucose levels in the diabetic range and three had IGT.
All patients had high levels of serum ferritin but no relationship was found with CGMS readings. However, there was a significant relation between compliance to iron-chelating therapy and abnormal glucose homeostasis in those patients. These data as well as ours proved that poor chelation and subsequently hemosiderosis of the pancreas and other organs appear to be a major cause for glycemic abnormalities in patients with β-TM. 19 This reinforces the importance of proper and early iron chelation or the use of intensive iron chelation in those with high iron load to decrease or reverse glycemic abnormalities. 45 In our study, the mean HbA1c of patients with RBG ≥7.8 mmol/L was 6.62 AE 1.51% and 12 (60%) patients had HBA1c values ≥6.5%. In this study, only 3 out of 20 (15%) of β-TM patients with RBG ≥7.8 mmol/L had insulin resistance using HOMA-IR. Two of them had DM using CGMS, while the third one had IGTT. Eight of 13 diabetic patients defined by CGMS (61.5%) had low fasting C peptide levels.
Insulin deficiency rather than insulin resistance was found in our study which is in agreement with other studies. 
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